PayerWatch

The rapid expansion of precision medicine, biologics, and targeted cancer therapies is transforming oncology—but it’s also overwhelming a system not built to keep pace. In the U.S., cancer drugs now account for some of the highest-cost treatments in healthcare, and with that has come a surge in prior authorization requirements and denials. Studies suggest physicians spend nearly two business days per week on administrative tasks like authorizations, contributing significantly to burnout and delayed care.So how can clinicians ensure patients receive timely, life-saving treatments in a system increasingly shaped by cost controls and automation? And more importantly—can AI become part of the solution rather than just a tool for denials?On this episode of PayerWatch, host Brian McGraw is joined by Dr. Arturo Loaiza-Bonilla, Co-Founder and Chief Medical AI Officer of Massive Bio, and Dr. Kendall Smith, Chief Medical Officer and Chief Physician Advisor at PayerWatch, for a conversation about oncology denials, prior authorization burden, and the emerging role of AI in appeals and access. Together, they examine how payer decision-making affects cancer patients, why clinical trialsPay are often overlooked in denial workflows, and how human oversight must remain central as AI becomes more common on both sides of the claims equation.Key Takeaways from the episode:Oncology denials are uniquely high stakes. Expensive biologics, chemo regimens, and precision therapies are often subject to heavier scrutiny, creating delays that can worsen outcomes and increase financial toxicity for patients.AI can help, but only with human oversight. The guests discuss how AI can support appeals, clinical trial matching, and documentation, while warning that hallucinated citations and unchecked outputs can undermine care decisions.Clinical trials should be considered earlier, not later. Instead of treating trials as a last resort or administrative complication, the episode argues they should be more proactively presented as care options that may reduce costs and expand access.Dr. Arturo Loaiza-Bonilla is a practicing medical oncologist and hematologist, as well as the Co-Founder and Chief Medical AI Officer of Massive Bio. He has spent years working at the intersection of oncology, patient access, and artificial intelligence, helping develop AI-driven tools that connect patients to clinical trials and treatment options. In the episode, he also references his leadership role in a large hematology-oncology network and his long-standing interest in applying data science and computational tools to real-world cancer care.Dr. Kendall Smith serves as Chief Medical Officer and Chief Physician Advisor at PayerWatch, where he brings deep expertise in chemotherapy and biologic denials, appeals strategy, and payer-provider disputes. His contributions to the episode focus on the practical realities of appeal workflows, the risks and opportunities of AI-assisted case preparation, and the importance of maintaining a human-in-the-loop approach when patient lives are on the line.

Healthcare providers across the U.S. are facing a growing wave of claim denials that is putting pressure on already strained hospital finances. Industry research from the American Hospital Association shows that nearly 15% of medical claims submitted to private payers are initially denied, forcing hospitals and health systems to spend about $19.7 billion annually attempting to overturn those denials through appeals and administrative processes. As payer rules grow more complex and denial rates climb, denial management is no longer just a revenue cycle task—it has become a strategic priority affecting operations, staffing, and even patient outcomes.But collecting denial data is only the first step. The real challenge is turning that information into meaningful improvements. How can healthcare organizations transform denial data into actionable insights that reduce denials, improve documentation, and ultimately protect both revenue and patient care?On this episode of PayerWatch, host Brian McGraw sits down with Reggie Allen, Chief Clinical/Business Operations at PayerWatch, and Dr. Kendall Smith, Chief Medical Officer and Chief Physician Advisor at PayerWatch, to unpack how organizations can use denial analytics to identify root causes, challenge payer behavior, and drive meaningful operational change. Their conversation explores the intersection of clinical documentation, payer accountability, and data integrity in modern healthcare revenue cycle management.Key topics discussed in this episode include:Why actionable denial data matters: How granular analytics can reveal root causes, from payer behavior to internal workflow gaps, allowing organizations to move from denial management to denial prevention.Holding payers accountable: Strategies for responding to questionable payer practices, including documenting approvals, citing regulations, and escalating disputes when necessary.Connecting denials to patient care: How revenue loss from denied claims can affect staffing, hospital resources, and ultimately the quality of care delivered to patients.Reggie Allen, RN, serves as Chief Clinical/Business Operations at PayerWatch. A nationally recognized expert in clinical denials and appeals, Allen brings decades of experience helping healthcare organizations overturn denials and develop proactive strategies to prevent them. His work focuses on leveraging denial analytics, operational insight, and regulatory knowledge to improve both revenue cycle performance and clinical documentation processes.Dr. Kendall Smith is the Chief Medical Officer and Chief Physician Advisor at PayerWatch. A hospitalist by training, Dr. Smith has extensive experience in utilization review, clinical documentation improvement (CDI), and payer dispute resolution. Throughout his career, he has worked closely with health systems to translate clinical data into operational improvements and advocate for fair payer practices.

Insurance denials aren’t new, but they’re hitting a breaking point right now. As prior authorizations surge and patients face longer delays for everything from imaging to specialty drugs, more providers are realizing that the “payer” on the card often isn’t the one truly holding the reins. A growing share of Americans are covered through self-funded employer plans governed by ERISA, which shifts timelines, appeal rights, and legal accountability away from state rules and toward federal standards—raising the stakes for patients, hospitals, and employers alike.So here’s the core question this episode tackles: when a denial happens, who actually has the power to fix it—and how do patients and providers use that leverage?In this episode of PayerWatch’s “Deny This,” host Brian McGraw sits down with Ann Lewandowski, Founder of Healthcare Rebel Alliance, to unpack the hidden mechanics of denials inside employer-sponsored plans. Together they explore how ERISA changes the denial game, why plan documents are the real rulebook, and what a more proactive employer oversight model could mean for reversing unfair decisions.Main points from the conversation:Denials fall into three buckets—and knowing which one you’re fighting matters. Ann breaks denials down into non-covered benefits, “insufficient information” administrative denials, and medical necessity denials tied to criteria like step therapy. Each requires a different fix and a different appeal strategy.If the plan is ERISA-regulated, state insurance rules don’t apply. Many people assume their state Department of Insurance protections cover them, but employer plans route through ERISA’s federal framework, including different timelines (often 15 days) and legal pathways.Plan documents are the ultimate authority—and employers have fiduciary risk. Ann explains that summary plan descriptions and full plan documents control coverage, even over PBM formularies. She highlights emerging legal pressure on plan administrators and employers to act in members’ best interests, especially in self-funded settings.Ann Lewandowski is the founder of Healthcare Rebel Alliance and an experienced healthcare utilization management professional with a background spanning population health, public health, and quality auditing. She began her healthcare career early through family involvement in small healthcare organizations, later moving into population health work at the California Department of Public Health starting in 2008. After transitioning into utilization management, she served as a Utilization Management Quality Auditor at Affinity Medical Solutions, where she reviewed denials and directly communicated prior-authorization decisions to patients and providers. In 2024, Ann took a public stand by suing her former employer for breach of fiduciary duty under its health plan—an experience that helped catalyze her rebrand and mission to empower patients, providers, and employers to push back against unjust denials.